Compare KPLT & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPLT | NSRX |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | Israel |
| Employees | 87 | 7 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 38.9M |
| IPO Year | N/A | N/A |
| Metric | KPLT | NSRX |
|---|---|---|
| Price | $6.24 | $3.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $19.67 |
| AVG Volume (30 Days) | 6.1K | ★ 12.5K |
| Earning Date | 05-07-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.62 | N/A |
| Revenue Next Year | $15.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $1.98 |
| 52 Week High | $24.15 | $9.99 |
| Indicator | KPLT | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 56.51 |
| Support Level | $5.89 | $2.83 |
| Resistance Level | $6.79 | $3.60 |
| Average True Range (ATR) | 0.49 | 0.21 |
| MACD | -0.11 | 0.04 |
| Stochastic Oscillator | 17.37 | 65.73 |
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.